高级检索
当前位置: 首页 > 详情页

The 150 most important questions in cancer research and clinical oncology series: questions 40-49

文献详情

资源类型:

收录情况: ◇ 统计源期刊 ◇ CSCD-C

机构: [1]School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, Guangdong, P. R. China. [2]Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. [3]Medical School of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. [4]Houston Methodist Hospital, Cancer Center and Research Institute, Houston, Texas, USA. [5]MD Anderson Cancer Center, Houston, Texas, USA. zhiminlu@mdanderson.org [6]Department of Pathology, Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, P. R. China. [7]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. [8]The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China. [9]Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. [10]The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
出处:
ISSN:

关键词: Mouse models Cervical cancer Anti-metastasis drug Cachexia Oligo-metastasis Warburg effect Epstein-Barr virus Lung cancer

摘要:
Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 10 more questions are presented as followed. Question 40. Why do mice being used as tumorigenesis models raised in different places or different conditions possess different tumor formation rate? Question 41. How could we generate more effective anti-metastasis drugs? Question 42. What is the molecular mechanism underlying heterogeneity of cancer cachexia in patients with the same pathologic type? Question 43. Will patients with oligo-metastatic disease be curable by immunotherapy plus stereotactic body radiotherapy? Question 44. Can the Warburg effect regulation be targeted for cancer treatment? Question 45. Why do adenocarcinomas seldom occur in the small intestine? Question 46. Is Epstein-Barr virus infection a causal factor for nasal natural killer/T cell lymphoma formation? Question 47. Why will not all but very few human papillomavirus-infected patients eventually develop cervical cancer? Question 48. Why do cervical carcinomas induced by human papilloma virus have a low mutation rate in tumor suppressor genes? Question 49. Can viral infection trigger lung cancer relapse?

语种:
WOS:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
第一作者:
第一作者机构: [1]School of Basic Courses, Guangdong Pharmaceutical University, Guangzhou, Guangdong, P. R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号